Latest Articles
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks
Published: April 13, 2026, 12:29 p.m.
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
Biontech prepares FDA application after strong phase II results in endometrial cancer medwatch.com
Published: April 13, 2026, 12:14 p.m.
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal - Stock Titan
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal Stock Titan
Published: April 13, 2026, 11:55 a.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - Sahm
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data Sahm
Published: April 13, 2026, 10:35 a.m.
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer - Stock Titan
GSK (NYSE: GSK) reports Mo-Rez data in ovarian, endometrial cancer Stock Titan
Published: April 13, 2026, 10:23 a.m.
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.
Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …
Published: April 13, 2026, midnight
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive
Published: April 12, 2026, 9:28 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9:01 p.m.
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
Link copied to clipboard!